Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,886 questions in 74 reviews · Skin
current versionsNo studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Etanercept vs cyclosporin Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs no corticosteroids Adverse effects leading to discontinuation of SJS/TEN therapy – not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs cyclosporin Adverse effects leading to discontinuation of SJS/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs no IVIG SJS/TEN‐specific mortality (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | RR 0.33 [0.04, 2.91] | 1 study · 36 participants | Very low |
Intravenous immunoglobulin (IVIG) vs no IVIG Time to complete re‐epithelialisation (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | 1 study · 36 participants | Very low |
Intravenous immunoglobulin (IVIG) vs no IVIG Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs no IVIG Total hospital length of stay (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | 1 study · 36 participants | Very low |
Moderate‐potency vs mild‐potency topical corticosteroid Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time within 1‐5 weeks) · children and adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | OR 2.07 [1.41, 3.04] | 4 studies · 449 participants | Moderate |
Potent vs moderate‐potency topical corticosteroid Patient‐reported symptoms of eczema: PGA; short‐term (week 1) · children and adults, most with moderate to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 2 studies · 192 participants | Low |
Potent vs moderate‐potency topical corticosteroid Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 10 studies · 541 participants | Low |
Potent vs moderate‐potency topical corticosteroid Systemic adverse events: abnormal cortisol; end of treatment (6 days to 4 weeks) · children and adults, most with moderate to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 3 studies · 99 participants | Very low |
Very potent vs potent topical corticosteroid Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐2 weeks) · adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | OR 0.53 [0.13, 2.09] | 3 studies · 243 participants | Low |
Very potent vs potent topical corticosteroid Patient‐reported symptoms of eczema: PGA (number judging excellent); short term (day 8) · adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 1 study · 116 participants | Very low |
Very potent vs potent topical corticosteroid Local adverse events: skin thinning; end of treatment (day 11‐day 22) · adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 2 studies · 233 participants | Very low |
Very potent vs potent topical corticosteroid Systemic adverse events: abnormal cortisol · adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 1 study · 117 participants | Very low |
Twice daily or more vs once daily topical corticosteroid Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | OR 0.97 [0.68, 1.38] | 15 studies · 1970 participants | Moderate |
Twice daily or more vs once daily topical corticosteroid Patient‐reported symptoms of eczema: PGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | OR 1.91 [0.62, 5.83] | 2 studies · 300 participants | Low |
Twice daily or more vs once daily topical corticosteroid Local adverse events: skin thinning; end of treatment (2‐6 weeks) · children and adults, most with moderate to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 11 studies · 1423 participants | Low |
Moderate‐potency vs mild‐potency topical corticosteroid Patient‐reported symptoms of eczema: 1‐5 weeks · children and adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 5 studies · 449 participants | Low |
Twice daily or more vs once daily topical corticosteroid Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 4 studies · 249 participants | Very low |
Longer‐term vs shorter‐term duration of use of topical corticosteroid Clinician‐reported signs of eczema · adults or children with eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Longer‐term vs shorter‐term duration of use of topical corticosteroid Patient‐reported symptoms of eczema · adults or children with eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Longer‐term vs shorter‐term duration of use of topical corticosteroid Local adverse events · adults or children with eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Longer‐term vs shorter‐term duration of use of topical corticosteroid Systemic adverse events · adults or children with eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Weekend therapy vs no topical corticosteroid Clinician‐reported signs of eczema: number of participants with one or more relapses (16‐20 weeks) · children and adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | RR 0.43 [0.32, 0.57] | 7 studies · 1149 participants | Moderate |
Weekend therapy vs no topical corticosteroid Patient‐reported symptoms of eczema: PGA (number judging excellent/good); end of treatment (20 weeks + 4 weeks acute phase) · children and adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | RR 2.25 [1.71, 2.96] | 1 study · 343 participants | Moderate |
Weekend therapy vs no topical corticosteroid Local adverse events: skin thinning; end of treatment (16‐20 weeks + 2‐4 weeks acute phase) · children and adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 7 studies · 1050 participants | Low |
Weekend therapy vs no topical corticosteroid Systemic adverse events: abnormal cortisol; end of treatment (16 weeks + 4 weeks acute phase) · children and adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 5 studies · 5 participants | Very low |
Moderate‐potency vs mild‐potency topical corticosteroid Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 4 studies · 472 participants | Low |
Moderate‐potency vs mild‐potency topical corticosteroid Systemic adverse events: abnormal cortisol; end of treatment (6‐28 days) · children and adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 2 studies · 33 participants | Very low |
Potent vs mild‐potency topical corticosteroid Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | OR 3.71 [2.04, 6.72] | 9 studies · 458 participants | Moderate |
Potent vs mild‐potency topical corticosteroid Patient‐reported symptoms of eczema: 1‐18 weeks · children and adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 5 studies · 483 participants | Moderate |
Potent vs mild‐potency topical corticosteroid Local adverse events: skin thinning; end of treatment (2‐18 weeks) · children and adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 5 studies · 440 participants | Low |
Potent vs mild‐potency topical corticosteroid Systemic adverse events: abnormal cortisol; end of treatment (6‐30 days) · children and adults with mild to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | no estimate extracted | 3 studies · 82 participants | Very low |
Potent vs moderate‐potency topical corticosteroid Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema Strategies for using topical corticosteroids in children and adults with eczema (2022) · Cochrane | OR 1.33 [0.93, 1.89] | 15 studies · 1173 participants | Moderate |
Skin care intervention vs standard skin care or no skin care intervention Eczema diagnosis by 1 to 3 years · infants age 12 months or younger Skin care interventions in infants for preventing eczema and food allergy (2022) · Cochrane | RR 1.03 [0.81, 1.31] | 7 studies · 3075 participants | Moderate |
Skin care intervention vs standard skin care or no skin care intervention IgE‐mediated food allergy (oral food challenge) by 1 to 3 years · infants age 12 months or younger Skin care interventions in infants for preventing eczema and food allergy (2022) · Cochrane | RR 2.53 [0.99, 6.49] | 1 study · 976 participants | Low |
Skin care intervention vs standard skin care or no skin care intervention Slippages (over the intervention period) · infants age 12 months or younger Skin care interventions in infants for preventing eczema and food allergy (2022) · Cochrane | RR 1.42 [0.67, 2.99] | 4 studies · 2538 participants | Low |
Skin care intervention vs standard skin care or no skin care intervention Skin infection (over the intervention period) · infants age 12 months or younger Skin care interventions in infants for preventing eczema and food allergy (2022) · Cochrane | RR 1.33 [1.01, 1.75] | 6 studies · 2728 participants | Moderate |
Skin care intervention vs standard skin care or no skin care intervention Stinging/allergic reactions to moisturisers (over the intervention period) · infants age 12 months or younger Skin care interventions in infants for preventing eczema and food allergy (2022) · Cochrane | RR 2.24 [0.67, 7.43] | 4 studies · 343 participants | Low |
Skin care intervention vs standard skin care or no skin care intervention Time to onset of eczema · infants age 12 months or younger Skin care interventions in infants for preventing eczema and food allergy (2022) · Cochrane | HR 0.86 [0.65, 1.14] | 9 studies · 3349 participants | Moderate |
Skin care intervention vs standard skin care or no skin care intervention Parent report of immediate reaction to common food allergen (at 2 years) · infants age 12 months or younger Skin care interventions in infants for preventing eczema and food allergy (2022) · Cochrane | RR 1.27 [1, 1.61] | 1 study · 1171 participants | Low |
Skin care intervention vs standard skin care or no skin care intervention Allergic sensitisation to a food allergen (at 1 to 3 years) · infants age 12 months or younger Skin care interventions in infants for preventing eczema and food allergy (2022) · Cochrane | RR 1.05 [0.64, 1.71] | 3 studies · 1794 participants | Low |
Oral methotrexate vs placebo Primary outcome: complete clinical response (malar/discoid rash) · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane | RR 3.57 [1.63, 7.84] | 1 study · 41 participants | Low |
Oral hydroxychloroquine vs placebo Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane | RR 0.49 [0.28, 0.89] | 1 study · 47 participants | Moderate |
Oral hydroxychloroquine vs placebo Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Oral hydroxychloroquine vs placebo Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Oral hydroxychloroquine vs placebo Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane | RR 3.9 [0.19, 78.46] | 1 study · 71 participants | Moderate |
Oral hydroxychloroquine vs placebo Adverse events: minor · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane | RR 1.32 [0.24, 7.19] | 1 study · 47 participants | Moderate |
Oral dehydroepiandrosterone vs placebo Primary outcome: complete clinical response · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane | RR 1.11 [1, 1.22] | 1 study · 381 participants | Moderate |